Not yet a member?Join now!|Lost password
Novo Nordisk A/S
Novo Nordisk A/S
12/03/2012 | Press release
Ryzodeg® (insulin degludec/insulin aspart) passed review by First Committee on Drugs of Pharmaceutical Affairs in Japan (3 December 2012)
distributed by noodls on 12/03/2012 05:50
Bagsværd, Denmark, 3 December 2012 - Novo Nordisk today announced that Ryzodeg® (insulin degludec/insulin aspart) has passed the review by the First Committee on Drugs of Japan's Pharmaceutical Affairs. The remaining step in the regulatory process is an approval from the Ministry of Health, Labour and Welfare.
Further information
| Media: | ||
| Mike Rulis | +45 4442 3573 | mike@novonordisk.com |
| Ambre Morley (US) | +1 609 216 5240 | abmo@novonordisk.com |
| Investors: | ||
| Kasper Roseeuw Poulsen | +45 4442 4303 | krop@novonordisk.com |
| Frank Daniel Mersebach | +45 4442 0604 | fdni@novonordisk.com |
| Lars Borup Jacobsen | +45 3075 3479 | lbpj@novonordisk.com |
| Jannick Lindegaard (US) | +1 609 786 4575 | jlis@novonordisk.com |
Company announcement No 78 / 2012
Who we are
Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 32,700 employees in 75 countries, and markets its products in 190 countries.
